Last reviewed · How we verify
Placebo to MK-8527
MK-8527 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells.
MK-8527 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo to MK-8527 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Glucokinase activator |
| Target | Glucokinase (GCK) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glucokinase activators increase the catalytic activity of glucokinase, an enzyme that acts as a glucose sensor in pancreatic beta cells. By enhancing glucokinase activity, MK-8527 promotes glucose-dependent insulin secretion, thereby improving glycemic control in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning insulin is released primarily when blood glucose is elevated, reducing hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disorders
- Headache
Key clinical trials
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (PHASE3)
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (PHASE3)
- A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014) (PHASE1)
- Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to MK-8527 CI brief — competitive landscape report
- Placebo to MK-8527 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI